US6701002056 - ADR
NOVO-NORDISK A/S-SPONS ADR
NYSE:NVO (4/26/2024, 7:07:16 PM)
After market: 127.3 +0.45 (+0.35%)126.85
+1.06 (+0.84%)
Novo Nordisk A/S is a DK-based company operating in Pharmaceuticals industry. Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
NOVO-NORDISK A/S-SPONS ADR
Novo Alle 1
Bagsvaerd 2880
P: 4544448888
CEO: Lars Fruergaard Jorgensen
Employees: 61412
Website: https://www.novonordisk.com/
The biotech's weight loss drug candidate could fuel a premium-laden buyout, but risks abound.
These stocks have tremendous potential, and it doesn't depend on the growth prospects for artificial intelligence.
Eli Lilly may be on the verge of another breakthrough, thanks to its hit GLP-1 medications.
Why NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) qualifies as a quality stock.
These three biotech stocks, with robust fundamentals and long-term prospects represent the sector’s finest at this time.
Here you can normally see the latest stock twits on NVO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: